New
research opens the door to 'functional cure' for HIV
Scripps Research
Institute
In findings that open
the door to a completely different approach to curing HIV infections,
scientists from the Florida campus of The Scripps Research Institute (TSRI)
have for the first time shown that a novel compound effectively suppresses
production of the virus in chronically infected cells, and prevents viral
rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI
Associate Professor Susana Valente, was published online Oct. 17 before print
in the journal Cell Reports.
"No other
anti-retroviral used in the clinic today is able to completely suppress viral
production in infected cells in vivo," Valente said. "When combining
this drug with the standard cocktail of anti-retrovirals used to suppress
infection in humanized mouse models of HIV-1 infection, our study found a
drastic reduction in virus RNA present -- it is really the proof-of-concept for
a 'functional cure.'"
Valente, a pioneer in this new approach, calls it "Block-and-Lock" -- the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her
colleagues use a derivative of a natural compound called didehydro-Cortistatin
A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral
transcriptional activator, called Tat, halting viral production, reactivation
and replenishment of the latent viral reservoir.
"Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation," Valente said. "It's important to note that our study uses the maximum tolerable dose of the drug -- with virtually no side effects."
The scientists studied
the combination therapy in a mouse model of HIV latency and persistence. Once
the combined treatment regimen was halted, viral rebound was delayed up to 19
days, compared with just seven days in mouse models receiving only
anti-retroviral treatment.
"This
demonstrates the potential of 'block-and-lock' strategies," said TSRI
Research Associate Cari F. Kessing, co-first author of the study. "This
study shows that a 'functional cure' approach can succeed in reducing residual
virus in the blood during anti-retroviral treatment and limiting viral rebound
during treatment interruption."
"In half of the
dCA treated mice, the virus was undetectable for 16 days after all treatment
was halted," said the University of North Carolina's Christopher Nixon,
another first author.
"We blocked Tat,
and the cell's machinery did the rest," said TSRI Research Associate Chuan
Li, a coauthor of the study. "The result was that the HIV promoter becomes
repressed."
Valente pointed out
that the animal models were exposed to just a single month of treatment.
"That's a relatively short period of time," she said. "We think
longer treatments will result in longer, or even permanent, rebound delays. The
question is how long? We're studying that now."
Because any viral
rebound of HIV comes with a host of adverse effects, Valente noted, blocking
that rebound would automatically reduce those effects.
"This is the only
class of drugs that stops infected cells from making viruses outright,"
said Valente. "All current antivirals work later in the viral lifecycle,
so only a HIV transcriptional inhibitor like dCA can stop the side effects of
low-level virus production."
In addition to
Valente, Kessing, Li and Nixon, other authors of the study, "In Vivo
Suppression Of HIV Rebound By Didehydro-1 Cortistatin A, A 'Block-And-Lock'
Strategy For HIV-1 Treatment," are Guillaume Mousseau and Mohammad Fallahi
of TSRI; Perry M. Tsai, Phong T. Ho, Jenna B. Honeycutt and J. Victor Garcia of
the University of North Carolina; and Hiroshi Takata and Lydie Trautmann of
Walter Reed Army Institute of Research and the Henry M. Jackson Foundation for
the Advancement of Military Medicine.
The study was
supported by the National Institutes of Health (grants R01AI097012,
R01AI118432, MH108179 and AI-111899), The Campbell Foundation and CARE, a
Martin Delaney Collaboratory (1UM1AI126619).
